Interleukin 7 - Revimmune SAS

Drug Profile

Interleukin 7 - Revimmune SAS

Alternative Names: CYT 107; Glycosylated recombinant human interleukin-7 - Cytheris; IL-7; Recombinant human interleukin-7 - Cytheris; rhIL-7; Second-generation CYT 99 007

Latest Information Update: 19 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cytheris
  • Developer Cognate BioServices; Cytheris; National Cancer Institute (USA); National Institute of Allergy and Infectious Diseases; Revimmune SAS; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; The French National Agency for Research on AIDS and Viral Hepatitis
  • Class Antineoplastics; Antivirals; Cytokines; Interleukins; Recombinant proteins
  • Mechanism of Action Immunomodulators; Interleukin 7 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Bladder cancer; Breast cancer; Colorectal cancer; HIV infections; Prostate cancer; Sepsis
  • Clinical Phase Unknown Idiopathic CD4-positive T-lymphocytopenia
  • Discontinued Bone marrow transplant rejection; Hepatitis B; Hepatitis C; Progressive multifocal leukoencephalopathy

Most Recent Events

  • 27 Aug 2018 Revimmune, Vanderbilt University School of Medicine and Washington University School of Medicine completes the phase II IRIS-7B for Sepsis in USA (IM) (NCT02640807)
  • 26 Jul 2018 Revimmune plans a phase I/II trial for Transplantation in USA , (NCT03600896)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top